Starpharma Holdings Ltd
ASX:SPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Starpharma Holdings Ltd
Total Equity
Starpharma Holdings Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Starpharma Holdings Ltd
ASX:SPL
|
Total Equity
AU$21.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-10%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Equity
-AU$18.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Equity
AU$370.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Equity
AU$338.5m
|
CAGR 3-Years
101%
|
CAGR 5-Years
69%
|
CAGR 10-Years
37%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Equity
AU$90.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Total Equity
AU$56.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
Starpharma Holdings Ltd
Glance View
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
See Also
What is Starpharma Holdings Ltd's Total Equity?
Total Equity
21.5m
AUD
Based on the financial report for Dec 31, 2025, Starpharma Holdings Ltd's Total Equity amounts to 21.5m AUD.
What is Starpharma Holdings Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
-10%
Over the last year, the Total Equity growth was -7%. The average annual Total Equity growth rates for Starpharma Holdings Ltd have been -19% over the past three years , -21% over the past five years , and -10% over the past ten years .
